Decision ruleHaematology
Smouldering myeloma progression risk (Mayo 2007 model)
Groups smouldering myeloma into three risk levels by marrow plasma cell percentage and serum monoclonal protein.
Updated 31 October 2026
When to use it
Patients with smouldering (asymptomatic) multiple myeloma at diagnosis, to estimate time to progression.
Warning
Model predates the 2014 IMWG criteria: with ≥ 60 % plasma cells, light-chain ratio ≥ 100 or > 1 focal MRI lesion the patient already has active myeloma. For current stratification prefer the 2/20/20 model.
What it needs
- Bone marrow plasma cells
- Serum monoclonal protein
How to interpret it
| Result | Interpretation |
|---|---|
| ≤ 0 | Not met: requires ≥ 10 % plasma cells or ≥ 3 g/dL monoclonal protein |
| 1 | Group 1 (both factors): median time to progression ≈ 2 years |
| 2 | Group 2 (plasma cells ≥ 10 %, protein < 3 g/dL): median ≈ 8 years |
| ≥ 3 | Group 3 (protein ≥ 3 g/dL, plasma cells < 10 %): median ≈ 19 years |
Practical tip
Overall progression risk is ≈ 10 % per year for the first 5 years and then falls (≈ 3 % per year for the next 5 and ≈ 1 % per year thereafter).
1 more practical tip in the app.
Reference
- Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356(25):2582-2590.
- Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-e548.
A support tool for healthcare professionals: it guides and does not replace clinical judgement.
